(secondQuint)Safety Study of Lactobacillus Administered Vaginally to Healthy Women.

 The purpose of this study is to demonstrate that the new formulation of L.

 crispatus CTV-05 (LACTIN-V) is safe and well tolerated in healthy pre-menopausal women when administered vaginally via a pre-filled applicator at a dose of 5.

0 x 10^8, 1.

0 x 10^9 or 2.

0 x 10^9 cfu/dose daily for 5 consecutive days as compared to a placebo control substance containing maltodextrin and a preservation matrix.

 Safety will be assessed by: - Incidence and severity of adverse events through assessing symptoms, physical examination findings, and signs of irritation involving the external genitalia, cervix or vagina, including disruption of the epithelium and blood vessels as seen on pelvic examination and colposcopy.

 - Laboratory parameters including urinalysis, a complete blood count (CBC) with differential, and chemistry panels to assess systemic effects of the study product.

 The study will also evaluate the tolerability and acceptability of LACTIN-V in a pre-filled applicator by: - The proportion of participants who discontinue study product use due to overt adverse events - The proportion of participants who adhere to the complete dosing schedule - Self-administered questionnaires and focus group discussions about acceptability of the study product.

 Safety Study of Lactobacillus Administered Vaginally to Healthy Women@highlight

The purpose of this study is to evaluate the safety, tolerability and acceptability of a new formulation of Lactobacillus crispatus, strain CTV-05 (LACTIN-V) in healthy pre-menopausal women.

 Osel, Inc.

 proposes that this new formulation will be safe and well-tolerated in healthy pre-menopausal women.

